Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
University of Oklahoma
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05297864CT.gov PARP Inhibition for Gliomas (PI-4G or π4g) | — | Terminated | — | — | — |
NCT05076513CT.gov Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Glioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Niraparib (this asset) | University of Oklahoma | P2 | CCC · 55 |
| Olutasidenib | Rigel Pharmaceuticals | P4 | BBB |
| Irinotecan | Kailin Yang, MD, PhD | P3 | B |
| Dianhydrogalactitol | Kintara Therapeutics, Inc. | P2 | B |
| Cyclophosphamide | Essen Biotech | P2 | B |
| Valproic Acid | Medical University of South Carolina | P2 | B |
| Nivolumab | Jason J. Luke, MD | P2 | B |
| Camustine | University of California, Davis | P3 | B |
| Thalidomide | Washington University School of Medicine | P2 | B |
+42 more in the Glioma cohort
Other indications for Niraparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P3 | BB · 67 |
| Ovarian Carcinoma | — | P4 | BB · 66 |
| Ovarian Neoplasm | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Niraparib in Glioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/niraparib-glioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →